RE:RE:RE:RE:Cash burn as usualSix months cash including Thomson line of credit. What part of "unable to know when they will be able to submit" don't you understand?. If it was on track, it would still be on slides as on track for H1 as it was on Q4 2019 presentation in March. I love the way you spell sur incorrectly on every one of your clowns. No one uses that short form in English, Pepito.
Newcamo wrote: Events in the future are always discussed in the same way. They project like when they said they target H1 2020, but as the time approaches they cant tell you 100% it will happened, if it comes 1 week later, you would su them. They told you riplazym as been tested in plant for 6 months, its a success. They met the FDA to submit and we're in may... plenty of time til end of june. Thats 2020 like they said in MDA! They can only say it that way. Same for partnership, this is going to be a money printing machine... im sur we'll find a distributer with $$$;)
6 months of cash, then SALP credit line if needed, THOMVEST owns lmnl, they finance companies like lmnl all the time if needed, money not a problem here...look at their website and all the businesses they manage, they know exactly what they are doing, owning 85% of all shares in lmnl. Quarters are not about money/revenues as u know at this point... but short term news. Thats why we are here;)